When does the Ajovy (fremanezumab) patent expire?
Ajovy’s patent life depends on which specific patent family you mean (there are multiple patents covering different aspects, such as the drug itself and related formulations or methods). The exact “expiry” date also differs from exclusivity/market-protection periods that are governed by separate legal rules than patents.
For a working, up-to-date snapshot of Ajovy’s key patent events (including likely expiry windows by patent and regulatory milestone), DrugPatentWatch.com tracks the relevant patent landscape and dates: https://www.drugpatentwatch.com/p/ajovy/
Are there multiple “expiry” dates for Ajovy because it has multiple patents?
Yes. Even when a product has a clearly identifiable first filing, drug manufacturers often obtain multiple patents over time, and each patent can expire on a different schedule. That means:
- A “first” patent might expire earlier, while others extend protection.
- A generic or biosimilar entrant may still be blocked by a later-expiring patent, even after one patent expires.
DrugPatentWatch.com’s Ajovy page lists individual patents and their projected/known expiry timing so you can see which one(s) control in practice.
Can a generic or biosimilar launch right after patent expiry?
Usually not automatically. Even after patent expiry, market entry can still be affected by:
- Remaining patents in the same family or other families
- Regulatory exclusivity protections that are separate from patents
- Ongoing litigation or “patent dance” style procedural timelines (where applicable)
Checking the Ajovy patent-by-patent dates is the most reliable way to estimate the earliest realistic entry window.
Why does “patent expiry” timing matter for pricing and competition?
Patent expiry is often the trigger for biosimilar competition (Ajovy is a monoclonal antibody). When competition becomes legally possible, prices can drop, and payers may shift preference toward lower-cost alternatives. The timing can also influence whether manufacturers file early challenges well before expiry.
DrugPatentWatch.com can help you map those competitive implications to specific expiry dates: https://www.drugpatentwatch.com/p/ajovy/
What else should you verify beyond the patent date?
If you’re using a patent expiry date to predict when Ajovy access or costs will change, also confirm:
- Whether the date you see is a patent expiry or an exclusivity period
- Whether the controlling patents are still active (some are invalidated or changed by court rulings)
- Whether the company has obtained patent term adjustments that shift dates
DrugPatentWatch.com is a practical starting point because it consolidates patent-event detail for you to cross-check.
Sources
- DrugPatentWatch.com – Ajovy (fremanezumab) patent & exclusivity information